Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions– Developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions –.

Kailera Therapeutics推出了4亿美元的A系列融资，以推进针对肥胖和相关疾病的下一代疗法组合-开发用于治疗肥胖和相关疾病的广泛，先进和差异化的临床阶段注射疗法和口服疗法组合。

– Lead clinical program, KAI-9531, an injectable GLP-1/GIP receptor dual agonist, demonstrated compelling results in Phase 2 trials in obesity and type 2 diabetes –

–领先的临床计划KAI-9531是一种可注射的GLP-1/GIP受体双重激动剂，在肥胖和2型糖尿病的2期试验中显示出令人信服的结果-

– Ron Renaud, Chief Executive Officer, will lead seasoned executive team with deep industry expertise; Industry veteran John F. Milligan named Chair of the Board –

–首席执行官罗恩·雷诺（RonRenaud）将领导经验丰富、拥有深厚行业专业知识的高管团队；行业资深人士John F.Milligan被任命为董事会主席——

– Financing co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital –BOSTON, October 1, 2024-- Kailera Therapeutics, Inc. (“Kailera” or “the Company”), today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions.

–由Atlas Venture、Bain Capital Life Sciences和RTW Investments共同领导的融资，由Lyra Capital（波士顿，2024年10月1日）参与，Kailera Therapeutics，Inc.（“Kailera”或“该公司”）今天宣布成立，作为一家临床阶段的生物制药公司，专注于推进下一代治疗肥胖和相关疾病的广泛渠道。

Kailera launches with a $400 million Series A financing co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital. The Company is developing several clinical-stage injectable and oral therapies that have demonstrated potential as best-in-class treatments for chronic weight management..

Kailera以Atlas Venture、Bain Capital Life Sciences和RTW Investments共同领导的4亿美元a系列融资启动，Lyra Capital参与了该项目。该公司正在开发几种临床阶段的注射和口服疗法，这些疗法已被证明是治疗慢性体重管理的最佳疗法。。

Kailera acquired exclusive rights for global development and commercialization of a portfolio of four metabolic disease assets outside of greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd (Hengrui), a leading global pharmaceutical company, in May 2024.

2024年5月，凯勒拉从全球领先的制药公司江苏恒瑞制药有限公司（恒瑞）收购了大中华区以外四种代谢疾病资产组合的全球开发和商业化专有权。

Kailera’s most advanced program, KAI-9531 (in development as HRS9531 in China) is an injectable GLP-1/GIP (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide) receptor dual agonist that demonstrated compelling results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including KAI-7535, a clinical-stage oral small molecule GLP-1 receptor agonist, KAI-9531 formulated as a once-daily oral tablet, and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist..

Kailera最先进的项目KAI-9531（在中国开发为HRS9531）是一种可注射的GLP-1/GIP（胰高血糖素样肽-1，葡萄糖依赖性促胰岛素多肽）受体双重激动剂，在中国肥胖和2型糖尿病的2期试验中取得了令人信服的结果。

“In this period of rapid innovation in the metabolic space, I believe that Kailera is poised to make an impact beyond the current market leaders. We have an incredible opportunity to develop next-generation treatments for chronic weight management, helping people reclaim their health and live their lives to the fullest,” said Ron Renaud, Chief Executive Officer, Kailera Therapeutics.

凯勒拉治疗公司首席执行官罗恩·雷诺（RonRenaud）表示：“在这一代谢领域快速创新的时期，我相信凯勒拉有望超越目前的市场领导者产生影响。我们有一个绝佳的机会来开发下一代慢性体重管理治疗方法，帮助人们恢复健康，充分享受生活。”。

'With a clinically-advanced, differentiated pipeline, a talented and experienced team with a track record for building companies with lasting impact, and the support of a world-class investor syndicate, we are uniquely positioned to advance innovative therapies that have the potential to meaningfully impact both quality of life and overall health for many people.”.

“凭借临床上先进的、差异化的渠道，一支有才华和经验丰富的团队，在建设具有持久影响力的公司方面有着良好的记录，以及世界级投资者财团的支持，我们处于独特的地位，可以推进创新疗法，这些疗法有可能对许多人的生活质量和整体健康产生重大影响。”

Mr. Renaud brings more than 25 years of biotech leadership to Kailera, with deep expertise in executive leadership, finance, and operations. As CEO of Cerevel Therapeutics, he guided the company through significant milestones, culminating in its acquisition by AbbVie in 2024. Previously, Mr. Renaud spearheaded Translate Bio’s growth from an early-stage startup to a publicly traded company, establishing it as a leader in mRNA technology.

雷诺先生为凯勒拉带来了超过25年的生物技术领导经验，在执行领导、财务和运营方面拥有深厚的专业知识。作为Cerevel Therapeutics的首席执行官，他带领公司走过了重要的里程碑，最终于2024年被AbbVie收购。此前，雷诺先生带领Translate Bio从一家早期初创公司成长为一家上市公司，使其成为mRNA技术的领导者。

As CEO of Idenix Pharmaceuticals, he streamlined operations and built a robust promising portfolio of potential treatments for hepatitis C..

作为Idenix Pharmaceuticals的首席执行官，他简化了运营，并建立了一套强大而有前景的丙型肝炎潜在治疗方案。

In conjunction with the launch, the Company also announced several key leadership appointments. Kailera’s seasoned management team brings deep industry experience and will be responsible for establishing operational infrastructure and driving critical milestones. The initial Kailera executive leadership team appointments include:.

在发布的同时，该公司还宣布了几项关键的领导任命。凯勒拉经验丰富的管理团队拥有丰富的行业经验，将负责建立运营基础设施和推动关键里程碑。Kailera执行领导团队的初始任命包括：。

• Doug Bakan, Ph.D., Chief Technology Officer, formerly of Ventyx Biosciences, Arena Pharmaceuticals, and Medicis Pharmaceutical

•Doug Bakan博士，首席技术官，曾供职于Ventyx Biosciences、Arena Pharmaceuticals和Medicis Pharmaceutical

• Paul Burgess, Chief Operating Officer and Chief Business Officer, formerly of Cerevel Therapeutics, Translate Bio, and Civitas

•Paul Burgess，首席运营官兼首席商务官，曾任职于Cerevel Therapeutics、Translate Bio和Civitas

• Paula Cloghessy, Chief People Officer, formerly of Seres Therapeutics, Translate Bio, and Joule Unlimited Technologies

•首席人事官Paula Cloghessy，前Seres Therapeutics、Translate Bio和Joule Unlimited Technologies

Additionally, John F. Milligan, Ph.D., has joined the Board of Directors as Chair. Dr. Milligan previously served as the President and Chief Executive Officer of Gilead Sciences, where he was instrumental in transforming the company from an early-stage private company into a global, multi-billion-dollar leader in biopharmaceuticals.

此外，John F.Milligan博士已加入董事会担任主席。Milligan博士曾担任Gilead Sciences的总裁兼首席执行官，在那里他帮助公司从早期的私营公司转变为全球数十亿美元的生物制药领导者。

Over the course of his three-decade tenure, he helped establish Gilead’s global presence and played a key role in the development and commercialization of over 25 innovative therapies, including the development of groundbreaking treatments for HIV and HCV..

在他三十年的任期内，他帮助建立了吉利德的全球影响力，并在超过25种创新疗法的开发和商业化中发挥了关键作用，包括开发针对艾滋病毒和丙型肝炎病毒的开创性疗法。

“I’m thrilled to join Kailera in their commitment to deliver next-generation therapies for obesity and related conditions,” said Dr. Milligan. “I look forward to working with the Kailera team to advance therapies with the potential to more comprehensively meet patients’ needs in short and long-term weight management and metabolic diseases, with a focus on improved efficacy and tolerability.”.

米利根博士说：“我很高兴能加入凯勒拉，致力于为肥胖和相关疾病提供下一代疗法。”。“我期待着与Kailera团队合作，推进治疗，有可能更全面地满足患者短期和长期体重管理和代谢疾病的需求，重点是提高疗效和耐受性。”

About Kailera Therapeutics

关于Kailera Therapeutics

Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China.

Kailera Therapeutics（Kailera）正在开发一种广泛，先进且有区别的临床阶段注射和口服疗法组合，用于治疗肥胖和相关疾病。Kailera最先进的项目KAI-9531（在中国开发为HRS9531）是一种可注射的GLP-1/GIP受体双重激动剂，在中国肥胖和2型糖尿病的2期临床试验中取得了积极成果。

The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA.

该公司还利用多种机制和递送途径（包括口服给药）推进多元化渠道。凯勒拉的使命是开发下一代体重管理疗法，使人们有能力改变生活，提高整体健康水平。该公司总部位于马萨诸塞州沃尔瑟姆和加利福尼亚州圣地亚哥。

For more information, visit www.kailera.com and follow us on LinkedIn and X.Contact: .

有关更多信息，请访问www.kailera.com，并在LinkedIn和X上关注我们。联系方式：